IL-1α or IL-1β suppression reduces cardiovascular risks in patients with late CKD stages, including ESRD and/or prolonged hemodialysis, but cost-effectiveness limits broad implementation of these strategies (95, 96, 157). The gene discussed is IL1B; the disease is chronic kidney disease.